REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) faces critical governance and compliance matters requiring shareholder approval at the 2025 Annual Meeting, detailed in its DEF 14A filing covering the period ended December 31, 2024.
Key Proposals and Compliance Risks: The Board strongly recommends two major proposals necessary for continued operation:
- Reverse Stock Split: Authorization for a 1-for-2 to 1-for-20 reverse split, exercisable at the Board’s discretion by December 31, 2026. This action is necessary to regain and maintain compliance with the Nasdaq Minimum Bid Price Requirem